Society of Nuclear Medicine and Molecular Imaging
Removal of the exclusionary language is an appropriate decision utilizing radiotracers currently FDA approved along with future tracers bearing FDA approval for PET scans.
I urge you, on behalf of patients who benefit from PET scans using current FDA approved tracers, to adopt inclusionary language for additional FDA approved tracers to the current CMS NCD coverage of PET scans. Streamlining of services with reliance of FDA approval of additional tracers will prove a cost savings for CMS but more importantly patients will benefit.
Laurel J. Pracht